Simplify Asset Management Inc. Acquires 425,626 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)

Simplify Asset Management Inc. raised its position in Leap Therapeutics, Inc. (NASDAQ:LPTX - Free Report) by 67.4% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,056,895 shares of the company's stock after acquiring an additional 425,626 shares during the period. Simplify Asset Management Inc. owned about 4.13% of Leap Therapeutics worth $2,716,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of LPTX. Vanguard Group Inc. raised its stake in Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company's stock valued at $2,308,000 after acquiring an additional 457,904 shares during the period. Acadian Asset Management LLC increased its position in Leap Therapeutics by 349.3% during the 1st quarter. Acadian Asset Management LLC now owns 282,413 shares of the company's stock worth $750,000 after buying an additional 219,563 shares during the period. Marshall Wace LLP increased its position in Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company's stock worth $156,000 after buying an additional 58,094 shares during the period. Finally, Key Client Fiduciary Advisors LLC increased its position in Leap Therapeutics by 22.2% during the 2nd quarter. Key Client Fiduciary Advisors LLC now owns 284,856 shares of the company's stock worth $558,000 after buying an additional 51,838 shares during the period. Institutional investors own 30.46% of the company's stock.

Leap Therapeutics Stock Down 5.2 %

Shares of LPTX traded down $0.15 during trading hours on Friday, hitting $2.74. 319,303 shares of the company were exchanged, compared to its average volume of 238,817. The company has a market cap of $70.14 million, a price-to-earnings ratio of -1.42 and a beta of 0.22. Leap Therapeutics, Inc. has a fifty-two week low of $1.34 and a fifty-two week high of $5.00. The firm's fifty day moving average is $2.94 and its 200 day moving average is $2.58.

Leap Therapeutics (NASDAQ:LPTX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.10). Analysts anticipate that Leap Therapeutics, Inc. will post -1.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $5.50 price objective on shares of Leap Therapeutics in a research report on Friday.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.